10 20 30 40 50 60 70 80 2G2A - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER CELL CYCLE 15-FEB-06 2G2A
TITLE ANGIOTENSIN II TYPE 2 RECEPTOR MODEL
COMPND MOL_ID: 1; COMPND 2 MOLECULE: TYPE-2 ANGIOTENSIN II RECEPTOR; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: ANGIOTENSIN II TYPE 2 RECEPTOR; COMPND 5 SYNONYM: AT2
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: RATTUS NORVEGICUS; SOURCE 3 ORGANISM_COMMON: RAT
KEYWDS GPCR PROTEIN, PROTEIN STRUCTURE MODELING BY SATISFACTION OF KEYWDS 2 SPATIAL RESTRAINTS, DOCKING
EXPDTA THEORETICAL MODEL
AUTHOR C.BALEANU-GOGONEA,M.WAGNER,S.KARNIK
REVDAT 1 27-FEB-07 2G2A 0
JRNL AUTH C.BALEANU-GOGONEA,M.WAGNER,S.KARNIK JRNL TITL THEORETICALLY PREDICTED STRUCTURE OF RAT JRNL TITL 2 ANGIOTENSIN II TYPE 2 RECEPTOR (AT2) AND THE JRNL TITL 3 LIGAND BINDING SITE JRNL REF TO BE PUBLISHED JRNL REFN
REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH T.OKADA,A.N.BONDAR,M.ELSTNER,P.ENTEL,V.BUSS REMARK 1 TITL THE RETINAL CONFORMATION AND ITS ENVIRONMENT IN REMARK 1 TITL 2 RHODOPSIN IN LIGHT OF A NEW 2.2 A CRYSTAL STRUCTURE REMARK 1 REF J.MOL.BIOL. V.342( 571 2004 REMARK 1 REFN ASTM JMOBAK UK ISSN 0022-2836
REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : MM2 87 REMARK 3 AUTHORS : ALLINGER, N.L. REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: THE 3-D MODEL OF AT2 RECEPTOR WAS REMARK 3 OBTAINED BY A COMBINATION OF SEQUENCE HOMOLOGY AND PROTEIN REMARK 3 STRUCTURE MODELING BY SATISFACTION OF SPATIAL RESTRAINTS , A REMARK 3 MODELING TECHNIQUE IMPLEMENTED IN THE PROGRAM MODELLER. THE REMARK 3 RESULTS OF THE RAMACHANDRAN MAP ANALYSIS PERFORMED WITH REMARK 3 PROCHECK PROGRAM VALIDATE THE QUALITY OF OUR AT2 3D MODEL. REMARK 3 FURTHER, WE PERFORMED DOCKING EXPERIMENTS WITH THE AGONIST, REMARK 3 ANG II (PDB#2AH3), [SAR1]ANGII, [SAR1-ILE4-ILE8]ANG II, AND REMARK 3 PD123319 ANTAGONIST.
REMARK 4 REMARK 4 2G2A COMPLIES WITH FORMAT V. 2.3, 09-JULY-1998
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 13-APR-2006. REMARK 100 THE RCSB ID CODE IS RCSB036598.
REMARK 220 REMARK 220 EXPERIMENTAL DETAILS REMARK 220 EXPERIMENT TYPE : THEORETICAL MODELLING REMARK 220 REMARK 220 REMARK: AT2 RECEPTOR BINDS HORMON ANGIOTENSIN II, AND PLAYS A REMARK 220 CRITICAL ROLE IN VASODILATATION, INHIBITION OF CELL REMARK 220 PROLIFERATION, INDUCTION OF APOPTOSIS, EXTRACELLULAR REMARK 220 MATRIX REMODELING AND AXONAL REGENERATION. THIS AT2 REMARK 220 RECEPTOR MODEL WAS CONSTRUCTED USING COMPUTATIONAL AND REMARK 220 HOMOLOGY MODELING TECHNIQUES FROM X-RAY STRUCTURE OF REMARK 220 BOVINE RHODOPSIN (1U19) AS A TEMPLATE. DOCKING REMARK 220 CALCULATION WERE PERFORMED ON ANGII AND ANG II ANALOGS REMARK 220 AND PD123319 ANTAGONIST LIGANDS. DEEP VIEW SWISS- REMARK 220 PDBVIEWER 3.7A1 WAS USED FOR PROCESSING AND PYMOL 0.97 REMARK 220 WAS USED FOR DATA ANALYSIS.
REMARK 225 REMARK 225 THEORETICAL MODEL REMARK 225 THE COORDINATES IN THIS ENTRY REPRESENT A MODEL STRUCTURE. REMARK 225 PROTEIN DATA BANK CONVENTIONS REQUIRE THAT CRYST1 AND REMARK 225 SCALE RECORDS BE INCLUDED, BUT THE VALUES ON THESE REMARK 225 RECORDS ARE MEANINGLESS.
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES: ENGH AND HUBER, 1991 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 VAL A 292 N - CA - C ANGL. DEV. = 16.1 DEGREES REMARK 500 LYS A 328 N - CA - C ANGL. DEV. = 15.6 DEGREES REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 VAL A 78 -94.60 94.03 REMARK 500 SER A 80 -147.82 105.56 REMARK 500 ASP A 141 -116.78 -150.96 REMARK 500 ARG A 142 -33.37 53.96 REMARK 500 TYR A 189 -95.93 63.71 REMARK 500 GLN A 253 -93.86 -170.67 REMARK 500 VAL A 292 -32.54 55.36 REMARK 500 LYS A 328 110.39 25.45 REMARK 500 LEU A 340 -43.50 62.77 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 GLY A 113 PRO A 114 148.52 REMARK 500 VAL A 115 MET A 116 142.76 REMARK 500 MET A 116 CYS A 117 121.07 REMARK 500 ILE A 287 ASN A 288 144.02
DBREF 2G2A A 1 363 UNP P35351 AGTR2_RAT 1 363
SEQRES 1 A 363 MET LYS ASP ASN PHE SER PHE ALA ALA THR SER ARG ASN SEQRES 2 A 363 ILE THR SER SER LEU PRO PHE ASP ASN LEU ASN ALA THR SEQRES 3 A 363 GLY THR ASN GLU SER ALA PHE ASN CYS SER HIS LYS PRO SEQRES 4 A 363 ALA ASP LYS HIS LEU GLU ALA ILE PRO VAL LEU TYR TYR SEQRES 5 A 363 MET ILE PHE VAL ILE GLY PHE ALA VAL ASN ILE VAL VAL SEQRES 6 A 363 VAL SER LEU PHE CYS CYS GLN LYS GLY PRO LYS LYS VAL SEQRES 7 A 363 SER SER ILE TYR ILE PHE ASN LEU ALA VAL ALA ASP LEU SEQRES 8 A 363 LEU LEU LEU ALA THR LEU PRO LEU TRP ALA THR TYR TYR SEQRES 9 A 363 SER TYR ARG TYR ASP TRP LEU PHE GLY PRO VAL MET CYS SEQRES 10 A 363 LYS VAL PHE GLY SER PHE LEU THR LEU ASN MET PHE ALA SEQRES 11 A 363 SER ILE PHE PHE ILE THR CYS MET SER VAL ASP ARG TYR SEQRES 12 A 363 GLN SER VAL ILE TYR PRO PHE LEU SER GLN ARG ARG ASN SEQRES 13 A 363 PRO TRP GLN ALA SER TYR VAL VAL PRO LEU VAL TRP CYS SEQRES 14 A 363 MET ALA CYS LEU SER SER LEU PRO THR PHE TYR PHE ARG SEQRES 15 A 363 ASP VAL ARG THR ILE GLU TYR LEU GLY VAL ASN ALA CYS SEQRES 16 A 363 ILE MET ALA PHE PRO PRO GLU LYS TYR ALA GLN TRP SER SEQRES 17 A 363 ALA GLY ILE ALA LEU MET LYS ASN ILE LEU GLY PHE ILE SEQRES 18 A 363 ILE PRO LEU ILE PHE ILE ALA THR CYS TYR PHE GLY ILE SEQRES 19 A 363 ARG LYS HIS LEU LEU LYS THR ASN SER TYR GLY LYS ASN SEQRES 20 A 363 ARG ILE THR ARG ASP GLN VAL LEU LYS MET ALA ALA ALA SEQRES 21 A 363 VAL VAL LEU ALA PHE ILE ILE CYS TRP LEU PRO PHE HIS SEQRES 22 A 363 VAL LEU THR PHE LEU ASP ALA LEU THR TRP MET GLY ILE SEQRES 23 A 363 ILE ASN SER CYS GLU VAL ILE ALA VAL ILE ASP LEU ALA SEQRES 24 A 363 LEU PRO PHE ALA ILE LEU LEU GLY PHE THR ASN SER CYS SEQRES 25 A 363 VAL ASN PRO PHE LEU TYR CYS PHE VAL GLY ASN ARG PHE SEQRES 26 A 363 GLN GLN LYS LEU ARG SER VAL PHE ARG VAL PRO ILE THR SEQRES 27 A 363 TRP LEU GLN GLY LYS ARG GLU THR MET SER CYS ARG LYS SEQRES 28 A 363 SER SER SER LEU ARG GLU MET ASP THR PHE VAL SER
HELIX 1 1 GLU A 45 GLN A 72 1 28 HELIX 2 2 ILE A 81 TYR A 103 1 23 HELIX 3 3 LYS A 118 ASP A 141 1 24 HELIX 4 4 ASN A 156 ALA A 160 5 5 HELIX 5 5 TYR A 162 PHE A 181 1 20 HELIX 6 6 SER A 208 ARG A 235 1 28 HELIX 7 7 MET A 257 LEU A 278 1 22 HELIX 8 8 LEU A 298 GLY A 322 1 25
SHEET 1 A 2 ASN A 4 SER A 6 0 SHEET 2 A 2 SER A 16 LEU A 18 -1 O SER A 16 N SER A 6
SSBOND 1 CYS A 35 CYS A 290 SSBOND 2 CYS A 117 CYS A 195
CISPEP 1 ALA A 194 CYS A 195 0 -27.04
CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 1.000000 0.000000 0.000000 0.00000
SCALE2 0.000000 1.000000 0.000000 0.00000
SCALE3 0.000000 0.000000 1.000000 0.00000